What are the ATA treatment guidelines for differentiated thyroid cancer?

Updated: May 14, 2020
  • Author: Pramod K Sharma, MD; Chief Editor: Arlen D Meyers, MD, MBA  more...
  • Print


A 2015 consensus statement from the American Thyroid Association on the management of patients with differentiated thyroid cancer who have recurrent/persistent nodal disease stated the following [1, 3] :

  • The appropriate management of patients with nodal metastases may involve compartmental lymph-node dissection, active surveillance (watchful waiting with serial cervical ultrasonographic evaluations), radioactive iodine ablation therapy, external-beam radiation therapy, and/or nonsurgical, image-guided, minimally invasive ablative approaches

  • Biologic considerations include aggressive histology, extrathyroidal extension of primary tumor, and molecular prognosis for aggressive biology

  • Surgical/technical considerations include prior recurrences in the same or different compartments

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!